NICE Recommends Approval for Ribociclib, Palbociclib for HR+/ HER2- Advanced Breast Cancer

December 21, 2017 – The United Kingdom’s National Institute for Health and Care Excellence (NICE) has issued guidance supporting approval for ribociclib and palbociclib for patients with hormone receptor-positive/HER2¬-negative locally advanced or secondary breast cancer. Both CDK4/6 inhibitors are indicated for use with an aromatase inhibitor (AI). If approved for routine National Health Service (NHS) use, about 8000 newly diagnosed patients in the … (leggi tutto)